A PSMA-targeted bispecific antibody for prostate cancer driven by a small-molecule targeting ligand-Reference-Cited by-同舟云学术

A PSMA-targeted bispecific antibody for prostate cancer driven by a small-molecule targeting ligand

Published:2021-08-13 Issue:33 Volume:7 Page:
ISSN:2375-2548
Container-title:Science Advances
language:en
Short-container-title:Sci. Adv.

Author:

Lee Sung Chang¹^ORCID,Ma Jennifer S. Y.¹,Kim Min Soo¹,Laborda Eduardo¹,Choi Sei-Hyun²,Hampton Eric N.¹^ORCID,Yun Hwayoung²^ORCID,Nunez Vanessa¹,Muldong Michelle T.³,Wu Christina N.⁴^ORCID,Ma Wenxue⁴^ORCID,Kulidjian Anna A.⁵,Kane Christopher J.⁴,Klyushnichenko Vadim¹,Woods Ashley K.¹,Joseph Sean B.¹^ORCID,Petrassi Mike¹,Wisler John¹^ORCID,Li Jing¹^ORCID,Jamieson Christina A. M.³^ORCID,Schultz Peter G.¹²^ORCID,Kim Chan Hyuk¹^ORCID,Young Travis S.¹²^ORCID

Affiliation:

1. Department of Biology, Calibr, The Scripps Research Institute, La Jolla, CA 92037, USA.

2. Department of Chemistry and Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.

3. Department of Urology, Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA.

4. Department of Medicine, Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA.

5. Department of Orthopedic Surgery, Scripps MD Anderson Cancer Center, La Jolla, CA 92093, USA.

Abstract

CCW702 is a bispecific antibody that combines the specificity of an imaging ligand with the potency of a T cell immunotherapy.

Funder

Wellcome

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference54 articles.

1. Cancer statistics, 2019

2. Nomogram Predicting Prostate Cancer–specific Mortality for Men with Biochemical Recurrence After Radical Prostatectomy

3. Very Early PSA Response to Abiraterone in mCRPC Patients: A Novel Prognostic Factor Predicting Overall Survival

4. Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer

5. Immunotherapy for prostate cancer: False promises or true hope?

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Progresses of T-cell-engaging bispecific antibodies in treatment of solid tumors;International Immunopharmacology;2024-09

2. A novel bispecific T-cell engager using the ligand-target csGRP78 against acute myeloid leukemia;Cellular and Molecular Life Sciences;2024-08-28

3. Reactions and adverse events induced by T-cell engagers as anti-cancer immunotherapies, a comprehensive review;European Journal of Cancer;2024-07

4. Bi-specific T-cell engagers (BiTEs) in prostate cancer and strategies to enhance development: hope for a BiTE-r future;Frontiers in Pharmacology;2024-05-30

5. Mono-amino acid linkers enable highly potent small molecule-drug conjugates by conditional release;Molecular Therapy;2024-04